Renaissance Technologies’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,012
| Closed | -$129K | – | 4070 |
|
|
2024
Q1 | $129K | Buy |
15,012
+10,110
| +206% | +$48.3K | ﹤0.01% | 3324 |
|
|
2023
Q4 | $17K | Sell |
4,902
-1,825
| -27% | -$6.42K | ﹤0.01% | 3602 |
|
|
2023
Q3 | $24K | Sell |
6,727
-447
| -6% | -$2.4K | ﹤0.01% | 3507 |
|
|
2023
Q2 | $42K | Sell |
7,174
-1,256
| -15% | -$23K | ﹤0.01% | 3648 |
|
|
2023
Q1 | $319K | Buy |
8,430
+1,678
| +25% | +$55K | ﹤0.01% | 3088 |
|
|
2022
Q4 | $201K | Buy |
6,752
+3,357
| +99% | +$102K | ﹤0.01% | 3419 |
|
|
2022
Q3 | $113K | Buy |
3,395
+765
| +29% | +$29.2K | ﹤0.01% | 3554 |
|
|
2022
Q2 | $105K | Buy |
2,630
+1,170
| +80% | +$45.3K | ﹤0.01% | 3839 |
|
|
2022
Q1 | $77K | Sell |
1,460
-9,090
| -86% | -$457K | ﹤0.01% | 3837 |
|
|
2021
Q4 | $584K | Sell |
10,550
-4,799
| -31% | -$306K | ﹤0.01% | 3002 |
|
|
2021
Q3 | $1.19M | Buy |
15,349
+6,672
| +77% | +$565K | ﹤0.01% | 2453 |
|
|
2021
Q2 | $1.13M | Sell |
8,677
-3,353
| -28% | -$464K | ﹤0.01% | 2614 |
|
|
2021
Q1 | $1.98M | Buy |
12,030
+3,575
| +42% | +$688K | ﹤0.01% | 2234 |
|
|
2020
Q4 | $1.98M | Buy |
8,455
+4,380
| +107% | +$610K | ﹤0.01% | 2119 |
|
|
2020
Q3 | $421K | Sell |
4,075
-9,795
| -71% | -$525K | ﹤0.01% | 2879 |
|
|
2020
Q2 | $544K | Buy |
13,870
+2,284
| +20% | +$90.4K | ﹤0.01% | 2845 |
|
|
2020
Q1 | $394K | Buy |
11,586
+4,010
| +53% | +$233K | ﹤0.01% | 2873 |
|
|
2019
Q4 | $355K | Buy |
7,576
+1,137
| +18% | +$74.7K | ﹤0.01% | 3021 |
|
|
2019
Q3 | $576K | Buy |
6,439
+393
| +7% | +$40.3K | ﹤0.01% | 2820 |
|
|
2019
Q2 | $822K | Buy |
6,046
+899
| +17% | +$142K | ﹤0.01% | 2784 |
|
|
2019
Q1 | $1.41M | Buy |
5,147
+942
| +22% | +$204K | ﹤0.01% | 2505 |
|
|
2018
Q4 | $530K | Buy |
4,205
+164
| +4% | +$44.5K | ﹤0.01% | 2849 |
|
|
2018
Q3 | $1.66M | Buy |
4,041
+441
| +12% | +$204K | ﹤0.01% | 2370 |
|
|
2018
Q2 | $1.94M | Buy |
3,600
+1,042
| +41% | +$554K | ﹤0.01% | 2273 |
|
|
2018
Q1 | $1.18M | Buy |
2,558
+1,234
| +93% | +$673K | ﹤0.01% | 2592 |
|
|
2017
Q4 | $887K | Buy |
1,324
+559
| +73% | +$337K | ﹤0.01% | 2711 |
|
|
2017
Q3 | $482K | Buy |
765
+212
| +38% | +$110K | ﹤0.01% | 2800 |
|
|
2017
Q2 | $265K | Buy |
553
+237
| +75% | +$145K | ﹤0.01% | 2934 |
|
|
2017
Q1 | $237K | Buy |
316
+114
| +56% | +$102K | ﹤0.01% | 2967 |
|
|
2016
Q4 | $197K | Buy |
202
+130
| +181% | +$149K | ﹤0.01% | 3008 |
|
|
2016
Q3 | $95K | Buy |
+72
| New | +$81.2K | ﹤0.01% | 3185 |
|
Other funds holding TCON
Renaissance Technologies's TCON Position: Q2 2024 in Review
Renaissance Technologies sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 15,012 shares — an estimated $129K sold.
Renaissance Technologies first reported a position in TCON in Q3 2016 and held it in 31 quarters. The position peaked at $1.98M in Q1 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Renaissance Technologies reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Renaissance Technologies sold 15,012 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $129K.
- Renaissance Technologies first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 31 quarters.
- Renaissance Technologies's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.98M in Q1 2021.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.